Arcellx (ACLX) Net Income towards Common Stockholders (2021 - 2025)
Arcellx (ACLX) recorded quarterly Net Income towards Common Stockholders of -$58.1 million in Q4 2025, down 4.18% quarter-over-quarter from -$55.8 million in Q3 2025, and down 23.43% on a YoY basis from -$75.9 million in Q4 2024.
Arcellx (ACLX) Net Income towards Common Stockholders (2021 - 2025) Analysis & Trends
Arcellx's Net Income towards Common Stockholders history runs 5 years deep, the most recent figure standing at -$58.1 million for Q4 2025.
- In Q4 2025, Net Income towards Common Stockholders fell 23.43% year-over-year to -$58.1 million; the TTM figure through Dec 2025 stood at -$228.9 million (down 113.39% YoY), while the FY2025 annual figure was -$228.9 million, down 113.26% from the prior year.
- Net Income towards Common Stockholders was -$58.1 million for Q4 2025 at Arcellx, down from -$55.8 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $19.8 million in Q4 2023 to a low of -$92.9 million in Q3 2022.
- Historically, Net Income towards Common Stockholders has averaged -$33.0 million across 5 years, with a median of -$27.3 million in 2023.
- The sharpest annual moves came in 2023 and 2025: Net Income towards Common Stockholders soared 150.89% in 2023, then tumbled 765.1% in 2025.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$20.7 million in 2021, then plunged by 88.39% to -$39.0 million in 2022, then jumped by 150.89% to $19.8 million in 2023, then tumbled by 337.26% to -$47.1 million in 2024, then fell by 23.43% to -$58.1 million in 2025.
- The last three Net Income towards Common Stockholders figures came in at -$58.1 million (Q4 2025), -$55.8 million (Q3 2025), and -$52.8 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -56.48 Mn |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | -58.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -58.11 Mn |
| Sep 30, 2025 | -55.78 Mn |
| Jun 30, 2025 | -52.77 Mn |
| Mar 31, 2025 | -62.27 Mn |
| Dec 31, 2024 | -47.08 Mn |
| Sep 30, 2024 | -25.84 Mn |
| Jun 30, 2024 | -27.16 Mn |
| Mar 31, 2024 | -7.20 Mn |
| Dec 31, 2023 | 19.84 Mn |
| Sep 30, 2023 | -39.34 Mn |
| Jun 30, 2023 | -23.85 Mn |
| Mar 31, 2023 | -27.34 Mn |
| Dec 31, 2022 | -38.99 Mn |
| Sep 30, 2022 | -92.87 Mn |
| Jun 30, 2022 | -30.77 Mn |
| Mar 31, 2022 | -26.04 Mn |
| Dec 31, 2021 | -20.70 Mn |
| Sep 30, 2021 | -17.11 Mn |
| Jun 30, 2021 | -15.93 Mn |
| Mar 31, 2021 | -11.28 Mn |